Kalaris Therapeutics (KLRS) awards 220,000 stock options to its CFO
Rhea-AI Filing Summary
Kalaris Therapeutics, Inc. reported an equity compensation grant to its Chief Financial Officer, Liisa Ann Bayko. On July 20, 2026, she received a stock option to acquire 220,000 shares of common stock at an exercise price of $4.00 per share, expiring on July 19, 2036.
According to the vesting schedule, 25% of the underlying shares vest on July 20, 2027, with the remaining shares vesting in equal monthly installments over the following three years, subject to continuous service. Following this award, she holds options covering 220,000 shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Bayko Liisa Ann
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1 | 220,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 220,000 shares (Direct)
Footnotes (1)
- F1. The option was granted on July 20, 2026. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on July 20, 2027 and the remainder vesting in equal monthly installments thereafter, subject to continuous service.
Key Figures
Options Granted: 220,000 options
Exercise Price: $4.00 per share
Underlying Shares: 220,000 shares
+3 more
6 metrics
Options Granted
220,000 options
Stock Option (Right to Buy) granted to CFO on July 20, 2026
Exercise Price
$4.00 per share
Conversion or exercise price of the stock option
Underlying Shares
220,000 shares
Common stock underlying the reported stock option
Expiration Date
July 19, 2036
Expiration date of the stock option award
Initial Cliff Vesting
25% on July 20, 2027
First tranche of option vesting subject to continuous service
Post-transaction Holdings
220,000 options
Total options held by the CFO after the reported grant
Key Terms
Stock Option (Right to Buy), exercise price, vesting, continuous service
4 terms
Stock Option (Right to Buy) financial
"security_title is listed as Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price is noted as the exercise price"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"shares underlying the option are scheduled to vest over four years"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
continuous service financial
"vesting is subject to continuous service"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Kalaris Therapeutics (KLRS) disclose for its CFO?
Kalaris Therapeutics disclosed that CFO Liisa Ann Bayko received a grant of 220,000 stock options on July 20, 2026. These options are a compensation award, not an open-market share purchase or sale, and give her the right to buy common stock at a fixed price.
How many stock options did the Kalaris Therapeutics (KLRS) CFO receive and at what price?
The CFO of Kalaris Therapeutics received 220,000 stock options with an exercise price of $4.00 per share. This means she can later purchase up to 220,000 shares of common stock at $4.00 each, subject to the options’ vesting conditions.
What is the vesting schedule for the KLRS CFO’s 220,000 stock options?
The 220,000 options vest over four years. 25% of the underlying shares vest on July 20, 2027, and the remaining 75% vest in equal monthly installments thereafter, as long as the CFO maintains continuous service with the company.
When do the Kalaris Therapeutics (KLRS) CFO’s new stock options expire?
The CFO’s 220,000 stock options expire on July 19, 2036. After this expiration date, any unexercised options will lapse and no longer provide the right to buy Kalaris Therapeutics common stock at the $4.00 exercise price.
How many options does the Kalaris Therapeutics (KLRS) CFO hold after this grant?
Following this reported transaction, the CFO holds options covering 220,000 shares of Kalaris Therapeutics common stock. This entire position reflects the newly granted option award reported in the Form 4 insider filing.